Semaglutide 0.5mg

Route: Subcutaneous injection, once weekly.

• Inject subcutaneously into the abdomen (periumbilical region), outer thigh, or posterior upper arm.
• Rotate injection sites each week to prevent lipodystrophy or injection site reactions.
• Administer on the same day each week; time of day is flexible (morning or evening, consistent with patient routine).
• Use an insulin syringe to draw the precise volume corresponding to 0.5 mg from the vial. Remove air bubbles before injecting.
• Do not inject into skin that is bruised, inflamed, or that has lipoatrophy.

Prescriber-determined. Context for 0.5 mg dosing:

• Type 2 diabetes (Ozempic labeling): 0.5 mg once weekly for at least 4 weeks; may escalate to 1.0 mg, then 2.0 mg based on glycemic response and tolerability.
• Weight management titration: 0.5 mg is an intermediate titration step in the Wegovy escalation protocol (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly).
• Do not escalate sooner than every 4 weeks; slower titration may reduce GI side effects.
• All dosing is determined by the prescribing clinician.

• Semaglutide: Binds GLP-1 receptors on pancreatic β-cells (glucose-dependent insulin release), α-cells (glucagon suppression), gut L-cells, and central neurons. In the hypothalamic arcuate nucleus, GLP-1R activation reduces orexigenic NPY/AgRP signaling and increases anorexigenic POMC/CART expression, collectively suppressing appetite and food intake. Delayed gastric emptying reduces postprandial glucose spikes and prolongs satiety. The week-long half-life is conferred by an albumin-binding fatty acid chain (C18 diacid) and an amino acid substitution at position 8 that prevents DPP-4 enzymatic degradation.

Indication context: 0.5 mg semaglutide is used as a maintenance dose for type 2 diabetes glycemic control (Ozempic) or as an intermediate dose step in weight management titration (Wegovy). At this dose, improvements in HbA1c (–1.0–1.5%) and body weight (–4–6%) have been demonstrated in pivotal trials.

Monitoring:

• HbA1c at 3 months; fasting glucose self-monitoring.
• Body weight monthly.
• GI tolerability assessment; if intolerable GI effects occur at 0.5 mg, prescriber may opt to extend time at 0.25 mg before escalating.
• Renal function (BUN/Cr) at baseline and periodically.
• Ophthalmology: if patient has background diabetic retinopathy, monitor for acceleration of retinopathy with rapid A1c improvement.

Contraindications:

• Personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
• Hypersensitivity to semaglutide.

Warnings & Precautions:

• Black box warning: thyroid C-cell tumors in rodents (human relevance unestablished); contraindicated in MTC/MEN2.
• Pancreatitis: discontinue if suspected acute pancreatitis.
• Diabetic retinopathy complications with rapid glycemic improvement.
• Hypoglycemia with concurrent insulin or sulfonylurea; reduce secretagogue doses as needed.

Drug Interactions:

• Oral medications: delayed gastric emptying may affect absorption kinetics of oral drugs.
• Insulin/sulfonylureas: increased hypoglycemia risk.

Common Side Effects: Nausea, vomiting, diarrhea, constipation, abdominal pain (all most common during initiation/escalation); injection site reactions.

Store refrigerated (2–8°C). Do not freeze. Protect from light. Once opened, use within the beyond-use date assigned by Genesis Compounding (typically within 28 days of first puncture). Keep out of reach of children. Do not shake the vial.

Why am I prescribed 0.5 mg specifically?

0.5 mg is either a titration-step dose on the way to a higher maintenance dose or a maintenance dose for type 2 diabetes glycemic control. Your prescriber has determined this dose based on your clinical response, tolerability, and treatment goals.

Can I inject this at any time of day?

Yes—semaglutide is once-weekly and can be injected at any time of day. Choose a consistent day and, ideally, a consistent time. It may be taken with or without food.

How long before I see results?

Glycemic improvements are typically seen within 4–8 weeks. Weight loss effects accumulate gradually over months. Maximum benefit in weight management is usually seen after 12–16+ weeks at maintenance dose.

Is this product FDA-approved?

Semaglutide is FDA-approved as Ozempic (0.5 mg and 1.0 mg, subcutaneous, for T2DM) and Wegovy (for weight management). This compounded preparation is a patient-specific 503A product from Genesis Compounding and is not FDA-approved as a compounded product.